



MaaT Pharma Releases its 2024 Financial Calendar

Lyon, France, March 7, 2024 – 6:00 pm CET – [MaaT Pharma \(EURONEXT: MAAT – the “Company”\)](#), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival for patients with cancer, releases its 2024 financial calendar*:

- March 28, 2024: Publication of 2023 annual financial results
- May 14, 2024: Publication of revenues for Q1 2024
- May 28, 2024: Annual General Shareholders Meeting
- September 19, 2024: Publication of half year financial results H1
- November 5, 2024: Publication of revenues for Q3 2024

**Indicative calendar could be subject to change.*

All information about the Company and its presentations to investors are available in the Investors section of its website: www.maatpharma.com/investors

About MaaT Pharma

MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint®, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. MaaT Pharma is listed on Euronext Paris (ticker: MAAT).



Contacts

MaaT Pharma – Investor Relations

Guillaume DEBROAS, Ph.D.
Head of Investor Relations
+33 6 16 48 92 50
invest@maat-pharma.com

MaaT Pharma – Media Relations

Pauline RICHAUD
Senior PR & Corporate Communications
Manager
+33 6 14 06 45 92
media@maat-pharma.com

Trophic Communications – Corporate Communications

Jacob VERGHESE or
Priscilla PERRIN
+49 151 7441 6179
maat@trophic.eu